Stocks · News reference
Filed: 2026-10-05 AccNo: 0001437749-26-031978 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Moleculin Biotech, Inc. (NASDAQ:MBRX) ("Moleculin" or the "Company") today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in
Moleculin Biotech announced the publication of a peer-reviewed cardiac safety analysis of Annamycin in Frontiers in Cardiovascular Medicine. A pooled analysis of five clinical trials involving 90 patients found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits, with independent evaluation by Cleveland Clinic supporting continued clinical development.